Your browser doesn't support javascript.
loading
Generation of two familial hypercholesterolemia patient-specific induced pluripotent stem cell lines harboring heterozygous mutations in the LDLR gene.
Gao, Jingshan; Li, Juana; Xu, Lingyun; Yan, Christopher D; Knowles, Joshua W; Wu, Joseph C.
Affiliation
  • Gao J; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Li J; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Xu L; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Yan CD; Greenstone Biosciences, Palo Alto, CA 94304, USA.
  • Knowles JW; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Center for Inherited Cardiovascular Disease, Stanford Health Care, Stanford, C
  • Wu JC; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: joewu@stanford.edu.
Stem Cell Res ; 78: 103463, 2024 Aug.
Article de En | MEDLINE | ID: mdl-38852422
ABSTRACT
Familial hypercholesterolemia (FH) is a genetic disorder affecting the metabolism of lipoprotein, characterized by elevated levels of plasma concentrations of low-density lipoprotein cholesterol (LDLC). The most common FH cause is mutations within the gene that encodes for the LDL receptor (LDLR) protein. Two induced pluripotent stem cell (iPSC) lines were generated from patients with FH, each carrying a single heterozygous mutation in the LDLR gene, one is a missense mutation, c.631C > T, and the other is a splice-site mutation, c.313 + 1G > A. Both iPSC lines exhibited strong expression of pluripotency markers, demonstrated the ability to differentiate into derivatives of the three germ layers, and maintained normal karyotypes. These derived iPSC lines represent powerful tools for in vitro modeling FH and offer a promising platform for therapeutic development.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs aux lipoprotéines LDL / Cellules souches pluripotentes induites / Hétérozygote / Hyperlipoprotéinémie de type II / Mutation Limites: Female / Humans / Male Langue: En Journal: Stem Cell Res Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs aux lipoprotéines LDL / Cellules souches pluripotentes induites / Hétérozygote / Hyperlipoprotéinémie de type II / Mutation Limites: Female / Humans / Male Langue: En Journal: Stem Cell Res Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique